Three startups get a push closer to the final kick
26.09.2018
Congratulations to AnnAidA Technologies, ONTrack Diagnostics and Neural Concept on bringing home CHF 20,000. These stage 2 Kickers have new approaches in microscopic nuclear magnetic resonance, deep learning algorithms and oncological diagnosis. Next step, the final kick and a chance to win CHF 130,000.
 AnnAidA Technologies
|
 |
 Neural Concept
|
|
 ONTrack Diagnostics
|
|
AnnAidA Technologies (EPFL) with Gaurasundar Conley – Medtech
AnnAidA Technologies (formerly EmbryoSpin) has developed technology for nuclear magnetic resonance operating at the scale of a single human embryo. The breakthrough enables non-invasive diagnostics that could greatly improve the success of in-vitro fertilisation, among other applications.
Neural Concept (EPFL) with Pierre Baqué – AI, CAE
Neural Concept optimizes industrial engineering processes using deep learning algorithms. Its solution allows companies to focus on core strategic choices, accelerate R&D cycles, reduce computational costs and leave the repetitive work to AI-empowered machines.
ONTrack Diagnostics (UZH) with Irina Banzola – Medtech
ONtrack Diagnostics is a medtech focusing on the development of non-invasive assays for screening, diagnosis and monitoring of oncological diseases. The first product is a urine assay for the screening of prostate cancer.
AnnAidA Technologies (formerly EmbryoSpin) has developed technology for nuclear magnetic resonance operating at the scale of a single human embryo. The breakthrough enables non-invasive diagnostics that could greatly improve the success of in-vitro fertilisation, among other applications.
Neural Concept (EPFL) with Pierre Baqué – AI, CAE
Neural Concept optimizes industrial engineering processes using deep learning algorithms. Its solution allows companies to focus on core strategic choices, accelerate R&D cycles, reduce computational costs and leave the repetitive work to AI-empowered machines.
ONTrack Diagnostics (UZH) with Irina Banzola – Medtech
ONtrack Diagnostics is a medtech focusing on the development of non-invasive assays for screening, diagnosis and monitoring of oncological diseases. The first product is a urine assay for the screening of prostate cancer.